Graduate-level education in translational medicine will require more than just scientif c research.
Af ordable and accessible health care is essential for a successful and productive society, yet the cost of therapy can prevent this goal from being realized. Providing universal access to af ordable high-quality health care requires not only advances in science, technology, policy, and clinical services but also more ef ective translation of technological innovations.
To cross the gap from lab bench to patient bedside, innovators must deal with issues related to product development, technology management, market positioning, cost/ reimbursement, and regulation. T us, specialized graduate education that teaches skills needed to negotiate the entire translational medicine continuum is invaluable for training the next generation of scientists, physicians, and managers; these colleagues can then work together at interdisciplinary interfaces in order to more ef ectively bridge the gap between bench and bedside. In this Focus, we discuss the essential components of such training using the joint "Master of Translational Medicine" (MTM) program of the University of California, Berkeley (UC Berkeley), and the University of California, San Francisco (UCSF), as an example.
UNIQUE SKILL SET
T e metrics of success for traditional advanced training in the biomedical sciences and engineering are usually publications and patents rather than products, but an advance at the bench that suggests a bedside improvement must be translated into a product if it is to have an impact on human health. T e translation process typically relies on funding sources quite dif erent from those that drive scientif c research and requires a dif erent set of skills to meet the business, management, design, regulatory, and clinical challenges. Training in these skills is typically not of ered or emphasized by traditional advanced degree programs (1, 2) .
For example, a physician-researcher with an intimate understanding of a clinical need may turn to a specialist engineer for their design experience, whereas an engineer with a novel medical sensor may require a regulatory expert to guide her through the U.S. Food and Drug Administration's (FDA's) 510(k) process. A Ph.D. or M.S. graduate may be qualif ed to lead R&D activities on the basis of their research experiences but is rarely qualif ed to contribute to other aspects of the translational process, such as regulatory issues, cost analysis, or clinical trials.
Graduates of MBA programs may have the business acumen to manage general operational and f nancial issues faced when bringing new technologies to market, but they may have little understanding of the product prof le, FDA regulatory pathways, specif c marketing requirements, or complications of health care insurance and reimbursement. Translational medicine needs an educational program designed to train leaders to work ef ectively in this complex space. A new generation of medical innovators must be taught to recognize, accept, and then ef ectively navigate the major challenges in translational medicine. Our experience as graduate educators has allowed us to compare new educational opportunities in translational medicine with those of traditional research-focused programs.
STUDENT COHORTS
Translational medicine education at the postgraduate level could be either a Master's program or an alternative training program for professionals, such as a Certif cate or Advanced Education program for clinicians or business executives. T e participants of such a program should be encouraged to come from a variety of backgrounds-engineering, physical sciences, law, business, pharmacy, and medicine-and may come from industry, from clinical training or practice, or directly from undergraduate education. It is with this melting pot of disciplines, experiences, and occupations that a program can be successful in cross-training translational experts.
In 2010, with the generous support of the Grove Foundation, UC Berkeley and UCSF initiated a 1-year joint MTM program (http:// bioeng.berkeley.edu/mtm). Applicants of en have an undergraduate degree in biomedical engineering, but many come from related educational backgrounds, including other engineering disciplines, biological sciences, pharmacy, and medicine. In general, applicants to the program share a common interest in medical technologies and, more specif cally, in learning how to transform new medical innovations into practical clinical solutions. Although the MTM program is intended to serve as a terminal degree for those students interested in an industry career, it can also provide supplemental translational training for those on the path to another advanced specialty (M.D., Ph.D., or MBA). Depending on the specif c career goals of each student, the MTM program is intended to train experts who can operate in a variety of translational settings, including labs, clinics, and corporations.
Because one of the primary goals of the MTM program is to fast-track students for success in medical technology-focused industries, the program specif cally targets early-career applicants. Many MTM applicants have just completed their undergraduate training, whereas others may have a few years of industry experience. A minority (typically 5 to 15%) of the applicants already hold advanced degrees and are of en skilled medical researchers or clinicians who are looking to supplement their professional or clinical skills with new training in the fundamentals of translation. T is diversity in the student population is crucial to a f eld that hinges on contributions from a broad spectrum of players: scientists who make new discoveries, engineers who design and build new technological solutions, business executives who navigate issues of f nance and marketing, regulatory agents who monitor and enforce the rules, and clinicians who use these newly approved medical technologies in their practices. T e goal of the MTM program is not to focus on a particular subset of these players but rather to of er a comprehensive view of translational medicine in order to accelerate
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and amplify the skills of those best poised to have an impact on medical innovation.
CURRICULUM COMPONENTS
Although translational medicine is clearly multifaceted, we believe that successful training in this discipline requires an understanding of three main subject areas: biomedical technology, clinical issues, and leadership and technology management (Fig. 1A) . Although every translational training program will be specif c to its sponsoring institution, most programs likely will share some of the fundamental features described in this section.
T e "biomedical technology" component focuses on technological solutions to unmet clinical needs. Although there are portions of the translational process that can be accomplished without a scientif c or engineering background, we believe that a fundamental understanding of the technology is paramount to successful translation. Before any medical innovation can help a patient in need, the technology must be well designed and well constructed. Without a sound technological solution as a starting point, the remaining steps in the translational pathway are meaningless. T e technology training can be customized to the needs and interests of students from different backgrounds.
T e "clinical issues" component is crucial for training students to recognize unmet clinical needs and for helping them to understand the additional factors involved when dealing with health care organizations and human subjects, such as FDA regulations, health care f nance, reimbursement, and the design of clinical trials. T ese issues distinctly separate the f eld of translational medicine from parallel industries dealing with nonmedical technologies. No matter how groundbreaking the technology is, a new medical product is likely to fail if it is not developed with a full consideration of the clinical and regulatory issues involved.
Yet, even good technologies that adhere to the regulatory policies can be prone to failure in the marketplace because of a lack of leadership or business savvy. T e "leadership" component of the MTM curriculum f lls this educational gap and is essential for successful product development. By training students to analyze new medical technologies from a business as well as a technological perspective, their chances for successful translation are enhanced. Identifying ways to reduce risk and learning to treat failures as opportunities for improvement are also essential parts of this educational component.
We believe that these three educational components are most ef ective when brought to bear in integrative team-based capstone projects in which students collaborate in real-world settings on newly developing technologies. In the MTM program, project proposals are submitted from a variety of prospective project leaders, including faculty members, clinical researchers, and industry partners. Each project addresses an unmet clinical need with a novel medical technology that is beyond the initial discovery phase (some proof-ofconcept has been demonstrated). Each project is discrete, the project leaders work with the program faculty to def ne the project goals for the year, and all projects aim toward the same long-term goal: to create a new medical innovation and translate it into clinical use.
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Ethical and social issues in translational medicine
Translational challenges in diagnostics, devices, and therapeutics
Technical electives on design, device, and drug delivery
Designing clinical research
Health care finance and economics
Regulatory issues and clinical trials
Engineering leadership
Biomedical technology
Clinical issues
Integrative team-based capstone project work Master's-level programs in translational medicine may currently be the most abundant option, but non-Master's training programs are emerging. For example, Tulane has a Ph.D. program in "Bioinnovation" that focuses on biosciences and entrepreneurship (https://tulane.edu/bioinnovation-IGERT). In 2005, the Howard Hughes Medical Institute (HMMI) launched its "Med into Grad" initiative, which has awarded $26 million in grant funding to help graduate students better interface with clinicians and f nd translational opportunities (www.hhmi.org/programs/ med-into-grad-initiative). T ere are also several entrepreneurship fellowship programs that bring together clinicians, engineers, and business professionals, during or a$ er their professional training, to develop products to meet clinical needs, such as the "Biodesign Innovation Fellowship" at Stanford (3) and the "Center for Device Development Fellowship" at Northwestern (http://cd2.northwestern. edu).T ese programs are typically 1 year in length and are o$ en intended for students who already hold an advanced degree.
Leadership and management of technology
Management of technology
Business electives
T e need for skilled professionals who can bring new medical technologies to the clinics quickly and ef ciently is clearly increasing, and the educational system is responding with greater options for training in translational medicine. Although these programs have developed largely independently of each other, their fundamental missions are similar: educate new leaders to excel in the f eld of medical technology translation so that they can transform the face of health care.
METRICS
As educational opportunities in translational medicine continue to expand as discussed above, the true impact of these programs will be felt when graduates apply their new training in the f eld. From our experience with the MTM program, we have seen alumni (n = 46 to date) move on to a variety of postgraduation opportunities (Fig. 1B) . For most students, this type of education serves as a terminal training program that will help graduates excel in the biotech or medtech industries.
Some graduates of these programs may choose to apply their new skills in a more clinical or academic setting, for example by using their new training as a supplemental tool in their careers. Other graduates may opt to pursue further academic training, such as a Ph.D., to become an expert in a particular technological area. T ese graduates will not only be able to discover and invent the medical innovations of the future but also have the translational skills to deliver these innovations to the people who need them.
In the MTM program, international students have become an increasingly important part of the cohort (growing from 7% in 2010 to 18% in 2013), and many are from emerging economic leaders, such as China and India. T ere are tremendous opportunities for welltrained international scientists and managers who understand how to interface with and navigate the U.S. regulatory and technological landscape. From just a few years of tracking our alumni, it is clear that educational programs focused on translational medicine can be extremely ef ective at placing young leaders in professional positions in which they can have a direct impact on the development of new medical technologies, both domestically and abroad.
Master's-level education in translational medicine is designed to accelerate the conversion of research f ndings into clinical treatments and provides interdisciplinary training in engineering, clinical science, regulatory issues, and business management. We believe that the multidisciplinary curriculum, the integrative team-based capstone projects, and the partnership with industry and medical centers are essential for the success of an educational program in translational medicine. Although several new educational programs are attempting to improve the bench-to-bedside process in this way, it is still too early to fully evaluate the broad impacts of these initiatives. We are encouraged by the steady demand from prospective applicants (64 applications in 2013) and by the early-stage successes of former students. For example, Gauss Surgical, Inc., is a company that originated from a MTM project. T e team was a f nalist in the USAID/Gates Saving Lives at Birth 2011 Grand Challenge and received two Forge Incubator grants from the Business Association of Stanford Entrepreneurial Students (BASES). T e company currently holds two 510(k) FDA clearances for its Pixel App. Intelligent Obstetrics, cofounded by a MTM alumnus, won the competition at Berkeley's Center for Entrepreneurship and Technology Venture Lab and was one of the f rst start-ups to join Berkeley's Skydeck incubator. At NanoNerve, Inc., several teams of MTM students have contributed to preclinical experiments and the successful SBIR Phase II project.
Long-term data tracking from alumni, clinicians, and industry professionals will be crucial to determining the deeper benef ts of this type of translational training. Although the exact metrics of success, which are dif erent from translational research (4), have not been well def ned, we believe that the quality of training and the number of graduates who go on to have careers primarily in medtech and biotech can be early indicators of a program's educational contribution to the f eld of translational medicine. Larger-scale and longer-term considerations of alumni career trajectory, salary, intellectual property development, and involvement in products that secure FDA approval will allow for more detailed analysis of the impact over time. T orough evaluation of the societal benef ts of such programs may require deeper examination of the medical technologies translated by program alumni, including health economics analyses, to determine how the graduates of these programs are making meaningful contributions to human health.
